Today's Research: Astex Pharma Inc., Delcath Systems Inc., BioMarin Pharma Inc., and Akorn Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, September 30, 2013 LONDON, September 30, 2013 /PRNewswire/ -- On Friday, September 27, 2013, the U.S. equity market ended on a lower note with the S&P 500 falling by 0.41% to end the day at 1,691.75; the Dow Jones Industrial Average declining by 0.46% to close at 15,258.24; and the NASDAQ Composite finishing at 3,781.59, down 0.15%. Shares in the healthcare sector ended mostly on a lower note, tracking losses in the broader market. The major movers in the sector included Astex Pharmaceuticals Inc. (NASDAQ: ASTX), Delcath Systems Inc. (NASDAQ: DCTH), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com has completed their technical analysis on ASTX, DCTH, BMRN, and AKRX and these free reports are accessible by registering at: http://www.aaaresearchreports.com/register/ Shares in Astex Pharmaceuticals Inc. edged lower on Friday, tracking losses in the broader market. The company's shares fluctuated between $8.47 and $8.51 before finishing the day 0.47% lower at $8.47. A total of 5.35 million shares were traded, which is above the daily average volume of 2.86 million. Despite Friday's pullback, the company's shares have rallied 106.08% in the last three months and 23.29% in the previous one month, compared to a gain of 5.32% and 3.60% in the S&P 500 during the respective periods. Furthermore, Astex Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $6.63 and $4.93, respectively. Sign up for free technical research on ASTX at: http://www.AAAResearchReports.com/ASTX093013.pdf Delcath Systems Inc.'s stock fell sharply on Friday, reversing all of the gains from the previous trading session. The company's shares closed the day 3.55% lower at $0.30 after fluctuating between $0.30 and $0.31 during the trading session. A total of 0.92 million shares were traded, which is below the daily average volume of 1.18 million. The company's shares have gained 0.95% in the previous three trading sessions, compared to a loss of 0.33% in the S&P 500 during the same period. Moreover, Delcath Systems Inc.'s stock is trading below its 50-day and 200-day moving averages of $0.36 and $0.93, respectively. Be sure to read our latest technical research on DCTH by registering at: http://www.AAAResearchReports.com/DCTH093013.pdf On Friday, BioMarin Pharmaceutical Inc.'s stock ended the session 0.05% lower than the previous day's price of $74.13. The company's shares oscillated between $73.65 and $74.60 before closing the day at $74.09. A total of 1.26 million shares were traded, which is below the daily average volume of 1.36 million. Despite Friday's losses, the company's shares have surged 12.51% in the last one month and 32.92% in the last three months, outperforming the S&P 500 which has gained 3.60% and 5.32% during the respective periods. Additionally, BioMarin Pharmaceutical Inc.'s stock is trading above its 50-day and 200-day moving averages of $67.74 and $61.02, respectively. Sign up and read the complimentary report on BMRN at: http://www.AAAResearchReports.com/BMRN093013.pdf Akorn Inc.'s shares rose sharply on Friday, extending the gains from the previous trading session. The company's shares vacillated between $18.44 and $19.22 before finishing the day 1.99% higher at $18.98. A total of 0.69 million shares were traded, which is at par with their daily average volume. The company's shares have gained 40.38% in the previous three months and 2.04% in the last three trading sessions, compared to a gain of 5.32% and a loss of 0.33% in the S&P 500 during the respective periods. Furthermore, Akorn Inc.'s stock is trading near its 52-week high of $19.47 as well as above its 50-day and 200-day moving averages of $16.72 and $14.53, respectively. The free report on AKRX can be downloaded by signing up now at: http://www.AAAResearchReports.com/AKRX093013.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: +1(646)396-9126, Peter F. Jones, Email ID: email@example.com
Today's Research: Astex Pharma Inc., Delcath Systems Inc., BioMarin Pharma Inc., and Akorn Inc.